Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause

Human Reproduction

Volumn 15, Issue 5, 2000, Pages 1028-1036

  Takahashi, Kentaro ^a   Okada, Masako ^a   Ozaki, Tomoya ^a   Kurioka, Hiroko ^a   Manabe, Atsushi ^a   Kanasaki, Haruhiko ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Bone metabolism; Climacteric symptoms; Hormone replacement therapy; Lipid metabolism; Oestriol

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; ESTRADIOL; ESTRIOL; FOLLITROPIN; LIPID; LUTEINIZING HORMONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE DENSITY; BREAST; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OVARIECTOMY; PATIENT SATISFACTION; SYSTOLIC BLOOD PRESSURE; VAGINA BLEEDING;

EID: 0034100515     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.5.1028     Document Type: Article

References (53)

1. Anderson, J.N., Peck, E.J. Jr and Clark, J.H. (1975) Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology, 96, 160-167.
2. Bairey, M.C.N., Kop, W., Krantz, D.S. et al. (1998) Cardiovascular stress response and coronary artery disease: evidence of an adverse postmenopausal effect in women. Am. Heart J., 135, 881-887.
3. Bergkvist, L., Adami, H-O., Persson, I. et al. (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N. Engl. J. Med., 321, 293-297.
4. Blum, M., Assa, S., Bacalu, B. et al. (1986) The influence of short-term estrogen replacement therapy (ERT) on the blood pressure and daily urinary catecholamine excretion in a small group of post-menopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol., 23, 195-199.
5. Bottiglione, F., Volpe, A., Esposito, G. et al. (1995) Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas, 22, 227-232.
6. Christiansen, M.S., Hagen, C., Christiansen, C. et al. (1982) Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am. J. Obstet. Gynecol., 144, 873-879.
7. Colditz, G.A., Hankinson, S.E., Hunter, D.J. et al. (1995) The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med., 332, 1589-1593.
8. Danser, A.M., Derkx, F.H., Schlekamp, M.A. et al. (1998) Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J. Hypertens., 16, 853-862.
9. Dubey, R.K., Gillespie, D.G., Jackson, E.K. et al. (1998) 17β-Estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension, 31, 522-528.
10. Erkkola, R., Lammintausta, R., Punnonen, R. et al. (1978) The effect of estriol succinate therapy on plasma renin activity and urinary aldosterone in postmenopausal women. Maturitas, 1, 9-14.
11. Esposito, G. (1991) Estriol: a weak estrogen or a different hormone? Gynecol. Endocrinol., 5, 131-53.
12. Ettinger, B., Li, D.-K. and Klein, R. (1998) Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil. Steril., 69, 865-869.
13. Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem., 18, 499-450.
14. Garnero, P., Sornay-Rendu, E., Chapuy, M.C. et al. (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res., 11, 337-349.
15. Grasso, A., Baraghini, F., Barbieri, C. et al. (1982) Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas, 4, 19-26.
16. Head, K.A. (1998) Estriol: safety and efficacy. Alternative Medicine Review, 3, 101-113.
17. Heimer, G.M. (1987) Estriol in the postmenopause. Acta Obstet. Gynecol. Scand. Suppl., 139, 5-23.
18. Heimer, G.M. and Englund, D.E. (1984) Enterohepatic recirculation of oestriol studied in cholecystectomized and non-cholecystectomized menopausal women. Upsala J. Med. Sci., 89, 107-115.
19. Hulley, S., Grady, D., Bush, T. et al. (1998) Randomized trial of estrogen plus, progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 280, 605-613.
20. Inoue, T., Kusida, K., Miyamoto, S. et al. (1983) Quantitative assessment of bone density on X-ray picture. J. Jpn Orthop. Assoc., 57, 1923-1936.
21. Keller, P.J., Riedmann, R., Fischer, M. et al. (1981) Oestrogens, gonadotropins and prolactin after intra-vaginal administration of oestriol in postmenopausal women. Maturitas, 3, 47-53.
22. Knopp, R.H. (1988) The effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet. Gynecol., 72, 23S-30S.
23. Kopera, H. (1983) Actions and potencies of estriol in the human. In Jasonni, V.M., Nenci, J. and Flamigni, C. (eds), Steroids and Endometrial Cancer. Raven Press, New York, pp. 175-183.
24. Kuiper, G., Enmark, E., Pelto-Hhuikko, M. et al. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl Acad. USA, 93, 5925-5930.
25. Kuiper, G., Carlsson, B. and Grandien, K. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 138, 863-870.
26. Kupperman, H.S., Wetchler, B.B. and Blatt, M.B.G. (1959) Contemporary therapy of the menopausal syndrome. JAMA, 171, 1627-1637.
27. Lauritzen, C. (1987) Results of a 5-year prospective study of estriol succinate treatment in patients with climacteric complaints. Horm. Metab. Res., 19, 579-584.
28. Leino, A., Jarvisalo, J., Impivaara, O. et al. (1994) Ovarian hormone status, life-style factors, and markers of bone metabolism in women aged 50 years. Calcif. Tissue Int., 54, 262-267.
29. Lemon, H.M. (1975) Estriol prevention of mammary carcinoma induced by 7,2,dimethyl-benzanthracene and procarbazine. Cancer Res., 35, 1341-1353.
30. Lindsay, R. and Cosman, F. (1990) Estrogen in prevention and treatment of osteoporosis. Ann. N. Y. Acad. Sci., 592, 326-33.
31. Lindsay, R. and Tohme, J.F. (1990) Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynecol., 76, 290-295.
32. Marslew, U., Overgaard, K., Riis, B.J. et al. (1992) The new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effect on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet. Gynecol., 79, 202-210.
33. Melis, G.B., Cagnacci, A., Bruni, V. et al. (1996) Salmon calcitonin plus intravaginal estriol: effective treatment for the menopause. Maturitas, 24, 83-90.
34. Mercuro, G., Zoncu, S., Piano, D. et al. (1998) Estradiol-17β reduces blood and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am. J. Hypertens., 11, 909-913.
35. Minaguchi, H., Uemura, T., Shirasu, K. et al. (1996) Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study. J. Obstet. Gynaecol. Res., 22, 259-265.
36. Modena, M.G., Rossi, R., Muia, N. Jr et al. (1998) Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension. Giornale Italiano di Cardiologia, 28, 636-644.
37. Nauck, M., Marz, W., Haas, B. et al. (1996) Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated. Clin. Chem., 42, 424-429.
38. Nishibe, A., Morimoto, S., Hirota, K. et al. (1998) Comparison of effects of estriol on bone mineral density of vertebrae between elderly and postmenopausal women. J. Bone Miner. Metab., 16, 21-26.
39. Okada, M., Takahashi, K., Kurioka, H. et al. (1995) Atypical uterine bleeding and serum estradiol level. J. Jpn. Menopause Soc., 3, 211-215.
40. Paech, K., Webb, P. and Kuiper, G. (1997) Differential ligand activation of estrogen receptors ER alpha and ER beta at API sites. Science, 277, 1508-1510.
41. Petersen, D.N., Tkalcevic, G.T., Koza-Taylor, P.M. et al. (1998) Identification of estrogen receptor β2, a functional variant of estrogen receptor β expressed in normal rat tissues. Endocrinology, 139, 1082-1092.
42. Saletu, B., Brandstatter, N., Metka, M. et al. (1995) Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal ocstradiol therapy in menopausal depression. Psychopharmacology, 122, 321-329.
43. Schiff, I., Wentworth, B., Koos, B. et al. (1978) Effect of estriol administration on the hypogonadal women. Fertil. Steril., 30, 278-282
44. Schneider, H.P.G. (1982) Oestriol and the menopause: clinical results from a prospective study. In Fioretti, P., Martini, L., Melis, G.B. and Yen, S.S.C. (eds), Serono Symposium, Vol. 39, The Menopause: Clinical, Endocrinological and Pathophysiological Aspects. Academic Press, London, pp. 523-533.
45. Serup, J., Bostofte, E., Larsen, S. et al. (1981) Effectivity and acceptability of oral contraceptives containing natural and artificial oestrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet. Gynaecol. Scand., 60, 203-206.
46. The ESHRE Capri Workshop (1998) Hormones and cardiovascular disease: oral contraceptives and hormonal replacement therapy: differential effects on coronary heart disease, deep venous thrombosis and stroke. Hum. Reprod., 13, 2325-2333.
47. Toy, J.L., Davies, J.A., McNicol, G.P. et al. (1978) The effects of long-term therapy with oestriol succinate on the haemostatic mechanism in postmenopausal women. Br. J. Obstet. Gynaecol., 85, 363-366.
48. Tzingounis, V.A., Aksu, F. and Greenblatt, R.B. (1978) Estriol in the management of the menopause. JAMA, 239, 1638-1641.
49. Tzingounis, V.A., Aksu, F. and Greenblatt, R.B. (1980) The significance of oestriol in the management of the post-menopause. Acta Endocrinol., 233, 45-50.
50. Vahapassi, J. and Adlercreutz, H. (1975) Effect of continuous oral administration of estriol on corpus luteum function. Contraception, 11, 427-439.
51. van Haaften, M., Donker, G.H., Gie-Go, D.M. et al. (1997) Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, and vagina of postmenopausal women. Gynecol. Endocrinol., 11, 175-185.
52. Weiderpass, E., Baron, J.A., Adami, H-O. et al. (1999) Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet, 353, 1824-1828.
53. Yang, T.S., Tsan, S.H., Chang, S.P. et al. (1995) Efficacy and safety of estriol replacement therapy for climacteric women. Chin. Med. J. (Taipei), 55, 386-391.